Rewind Therapeutics Secures Additional Financing to Advance Oral GPR17 Remyelination Program
- Financing will be used to advance Rewind’s lead oral program designed to promote remyelination and restore neurological function
- Peer-reviewed data published in PLOS ONE demonstrated remyelination and functional recovery following oral treatment with a selective GPR17 antagonist in preclinical models
Leuven, Belgium – 6 October 2026 – Rewind Therapeutics (“Rewind”), a biotechnology company developing small-molecule therapies to restore myelin in demyelinating diseases, today announced that it has secured additional financing to advance the development of its lead GPR17 antagonist program, a potential disease modifying oral therapy intended to promote remyelination and restore neurological function in multiple sclerosis (MS).
